Pharmaceutical

ASCO25: Merck KGaA to seek approval of TGCT drug after Phase III success

Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase III TGCT trial.

May 30, 2025 - 06:00
ASCO25: Merck KGaA to seek approval of TGCT drug after Phase III success
Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase III TGCT trial.
Read the original article

Tags:

Previous Article

EC approves BMS’ nivolumab SC formulation for solid tumours

Next Article

Scynexis resumes dosing in Phase III MARIO study after lengthy delay

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: STAT+: How payer-participating trials could help transform clinical research on FDA-approved drugs

Opinion: STAT+: How payer-participating trials could he...

Oct 6, 2023

Otsuka Pharmaceutical agrees to buy Mindset Pharma

Otsuka Pharmaceutical agrees to buy Mindset Pharma

Sep 1, 2023

A needle-free anaphylaxis treatment runs into an FDA roadblock

A needle-free anaphylaxis treatment runs into an FDA ro...

Sep 20, 2023